Sign up
NCNA

NuCana PLC (NASDAQ: NCNA)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. Short interest is 3.23% of float with a 4.91% borrow fee. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

Momentum—

—

Trend—

—

Short interest3.2% of float

FINRA settlement Oct 30, 2026

NCNA price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range
$0.83 – $4.43Through Nov 18, 2026
Volume—
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$4.20M
P/E (TTM)0.0
Forward P/E—
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)2.41

Price history

NCNA · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide33Calm Tide—
Squeeze26Idle—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

— · Earnings history not available

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

All NCNA news →

Company profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside

CEO
Mr. Hugh Stephen Griffith
Headquarters
Edinburgh, United Kingdom
Employees
10
IPO date
Sep 28, 2017
Sector
Healthcare
Industry
Biotechnology
Website
nucana.com

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.